Hexarelin vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Examorelin, HEX
Hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or GHRP) that pushes the pituitary to release growth hormone. What makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. It is a research compound, not an approved drug, and almost all of the heart data is from animals.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), built from a modified GRF(1-29) sequence with four amino acid swaps plus a Drug Affinity Complex (DAC) that lets it latch onto your own albumin after injection. That albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and IGF-1 up for over a week. It is not FDA approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Hexarelin | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hexarelin acts through two different receptors, which is the key to understanding it. The first is the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor in the pituitary, which is how it triggers growth hormone release. The second is CD36, a scavenger receptor found on heart muscle cells and small blood vessels, and this is where its cardioprotective story lives. Activating CD36 in the heart has been shown to improve coronary flow and protect heart tissue from ischemia (low oxygen) and reperfusion injury, and crucially these effects still happen in growth-hormone-deficient animals, proving the heart benefit is separate from the GH benefit. | GHRH is the natural signal your hypothalamus sends to the pituitary to release growth hormone in pulses. CJC-1295 binds and activates the same GHRH receptor on the pituitary, prompting it to make and release more of its own growth hormone, which then raises IGF-1 from the liver. The four amino acid substitutions make it resist breakdown by the enzyme DPP-IV, and the DAC linker covalently bonds it to circulating albumin so it is not cleared quickly. Because it amplifies the body's own pulsatile signaling rather than injecting growth hormone directly, the effect is a sustained elevation rather than a single spike. |
| Common Dosing | 100-200 mcg 2-3x daily 2-3x daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 4-8 weeks (desensitization occurs) | 8-12 weeks typical |
| Best Time to Take | Morning and before bed (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The growth hormone-releasing effect of hexarelin is well established in humans from older endocrine research, but the exciting cardiovascular claims are still mostly preclinical. The landmark mechanistic work (Circulation Research, 2002) identified CD36 as the receptor through which growth hormone-releasing peptides act on the heart, and follow-up rodent studies showed hexarelin improves left ventricular function and protects cardiomyocytes from ischemia-reperfusion injury, in one case through interleukin-1 signaling (2017). A 2014 review in the Annals of the New York Academy of Sciences and a 2017 PMC review both lay out a plausible cardioprotective case. But here is the honest part: there are no large modern human trials showing hexarelin treats or prevents heart disease in people, and a known limitation is rapid tolerance, the GH response fades with continued use. So the cardiac angle is genuinely interesting biology, not an established therapy. | The core human evidence is a single early-phase study, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy adults. A single subcutaneous dose raised GH roughly 2 to 10 fold and IGF-1 about 1.5 to 3 fold, with GH staying up for 6 days or more and IGF-1 elevated for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days. The estimated half-life was about 5.8 to 8.1 days and no serious adverse reactions were reported in that short trial. Beyond that, the data is mostly animal work, such as a study showing once-daily CJC-1295 normalized growth in GHRH knockout mice. Importantly, clinical development by the original sponsor (ConjuChem) was stopped, and a related long-acting analog program saw a Phase II lipodystrophy study halted after a participant death, although the attending physician attributed that death to pre-existing coronary disease rather than the drug. So the honest read is: short-term pharmacology in humans is documented, but there are no long-term safety or efficacy trials, no approval, and real questions about chronically elevating IGF-1. |
Frequently Asked Questions: Hexarelin vs CJC-1295 DAC
What is the difference between Hexarelin and CJC-1295 DAC?
Hexarelin is a growth hormone peptide that hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or ghrp) that pushes the pituitary to release growth hormone. what makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. it is a research compound, not an approved drug, and almost all of the heart data is from animals. CJC-1295 DAC is a growth hormone peptide that cjc-1295 dac is a synthetic, long-acting analog of growth hormone-releasing hormone (ghrh), built from a modified grf(1-29) sequence with four amino acid swaps plus a drug affinity complex (dac) that lets it latch onto your own albumin after injection. that albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and igf-1 up for over a week. it is not fda approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Hexarelin or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. Hexarelin is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Hexarelin and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Hexarelin and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.